Wiernik Ph
About
In The Last Decade
Wiernik Ph
96 papers receiving 2.9k citations
Peers
Comparison fields: 5 of 108
- Hematology 1.7k
- Oncology 1.1k
- Molecular Biology 729
- Public Health, Environmental and Occupational Health 586
- Genetics 379
Countries citing papers authored by Wiernik Ph
This map shows the geographic impact of Wiernik Ph's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wiernik Ph with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wiernik Ph more than expected).
Fields of papers citing papers by Wiernik Ph
This network shows the impact of papers produced by Wiernik Ph. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wiernik Ph. The network helps show where Wiernik Ph may publish in the future.
Co-authorship network of co-authors of Wiernik Ph
This figure shows the co-authorship network connecting the top 25 collaborators of Wiernik Ph. A scholar is included among the top collaborators of Wiernik Ph based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wiernik Ph. Wiernik Ph is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 25 | |
| 2 | 19 | |
| 3 | 16 | |
| 4 | 60 | |
| 5 | 43 | |
| 6 | 82 | |
| 7 | 25 | |
| 8 | Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma. | 102 |
| 9 | Intensive maintenance therapy improves survival in adult acute nonlymphocytic leukemia: an eight-year follow-up. | 20 |
| 10 | Rifampin and cloxacillin in the reduction of Staphylococcus aureus colonization. | 1 |
| 11 | Phase II trial of methyl-G (methylglyoxal bis-guanylhydrazone) in patients with metastatic renal cell carcinoma. | 4 |
| 12 | High-dose VP 16-213 (NSC 141540) for the treatment of patients with previously treated acute leukemia. | 21 |
| 13 | A comparative trial of tobramycin vs gentamicin in combination with vancomycin and nystatin for alimentary tract suppression in leukemic patients. | 11 |
| 14 | 1 | |
| 15 | In vitro antibacterial activity of four aminoglycosides and two semisynthetic penicillins on fresh clinical isolates from cancer patients. | 3 |
| 16 | 46 | |
| 17 | Phase II study of azotomycin in sarcomas. | 1 |
| 18 | Modulating effects of levamisole (NSC-177023) on human lymphocyte response in vitro. | 26 |
| 19 | Combination therapy with 5-azacytidine (NSC-102816) and methyl-GAG (NSC-32946) in previously treated adults with acute nonlymphocytic leukemia. | 9 |
| 20 | Development of herpes zoster in a patient with acute leukemia after therapy with cytosine arabinoside (NSC-63878). | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.